<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107717">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02041663</url>
  </required_header>
  <id_info>
    <org_study_id>AOR 10106</org_study_id>
    <nct_id>NCT02041663</nct_id>
  </id_info>
  <brief_title>Septic cArdiac Deficiency and MenIngococcal seveRe Sepsis</brief_title>
  <acronym>SAMIRA</acronym>
  <official_title>Septic cArdiac Deficiency and MenIngococcal seveRe Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <authority>France: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Use of brain natriuretic peptide to evaluate the cardiac function in the course of
      meningococcal septic shock or severe sepsis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: determining sensibility and specificity of BNP blood level to detect myocardial
      dysfunction in septic shock or severe sepsis due to Neisseria meningitidis in children.

      METHODS: Prospective multicentric clinical trial including 7 French pediatric intensive care
      units. Serial cardiac ultra sounds and blood sampling will be done for patients hospitalized
      for purpura fulminans beginning at the time of admission in pediatric intensive care. Any
      child from 6 months to 18 years without preexisting cardiac disease and presenting with
      purpura fulminans will be enrolled after obtaining consent of both parents. From adult's
      studies on septic shock and BNP, a total number of 30 patients was calculated to be
      necessary to prove the interest of BNP in this indication.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Repeated brain natriuretic peptide (BNP) blood level</measure>
    <time_frame>Up to day 5</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Repeated cardiac  echography</measure>
    <time_frame>Up to day 5</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PRISM II gravity score</measure>
    <time_frame>Up to day 5</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ failure PELOD score</measure>
    <time_frame>Up to day 5</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Troponin rate</measure>
    <time_frame>Up to day 5</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality and morbidity (aftereffects)</measure>
    <time_frame>Day 28 and hospital discharge</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Meningococcal Infections</condition>
  <condition>Septic Shock</condition>
  <condition>Severe Sepsis</condition>
  <arm_group>
    <arm_group_label>Population</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Repeated brain natriuretic peptide dosages and cardiac echographies up to day 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BNP</intervention_name>
    <description>Repeated brain natriuretic peptide dosages and cardiac echographies up to day 5</description>
    <arm_group_label>Population</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children

          -  6 months to 18 years aged

          -  without previous cardiac pathology

          -  hospitalized in the participating pediatric intensive care units for serious sepsis
             with extensive purpura

        Exclusion Criteria:

          -  Heart malformative disorder with right-left shunt

          -  Pre-existent known cardiac insufficiency whatever is the origin

          -  Concomitant participation in another trial

          -  Patient in period of exclusion from another trial

          -  Not membership in a national insurance scheme
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Bergougnoux, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean Bergounioux, MD</last_name>
    <phone>+33 (0)1 44 49 42 18</phone>
    <email>jean.bergounioux@nck.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>AP-HP, Necker hospital</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Bergougnoux, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean Bergougnoux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 20, 2014</lastchanged_date>
  <firstreceived_date>January 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>brain natriuretic peptide</keyword>
  <keyword>cardiac function</keyword>
  <keyword>meningococcal infections</keyword>
  <keyword>septic shock</keyword>
  <keyword>severe sepsis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Meningococcal Infections</mesh_term>
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Natriuretic Peptide, Brain</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
